PT2499165T - Preparações que contêm o fator de von willebrand (vwf), e métodos, kits e utilizações relacionadas com as mesmas - Google Patents

Preparações que contêm o fator de von willebrand (vwf), e métodos, kits e utilizações relacionadas com as mesmas

Info

Publication number
PT2499165T
PT2499165T PT108307778T PT10830777T PT2499165T PT 2499165 T PT2499165 T PT 2499165T PT 108307778 T PT108307778 T PT 108307778T PT 10830777 T PT10830777 T PT 10830777T PT 2499165 T PT2499165 T PT 2499165T
Authority
PT
Portugal
Prior art keywords
vwf
kits
methods
von willebrand
willebrand factor
Prior art date
Application number
PT108307778T
Other languages
English (en)
Inventor
Barnett Thomas
Original Assignee
Grifols Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Therapeutics Inc filed Critical Grifols Therapeutics Inc
Publication of PT2499165T publication Critical patent/PT2499165T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT108307778T 2009-11-13 2010-11-12 Preparações que contêm o fator de von willebrand (vwf), e métodos, kits e utilizações relacionadas com as mesmas PT2499165T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26114509P 2009-11-13 2009-11-13

Publications (1)

Publication Number Publication Date
PT2499165T true PT2499165T (pt) 2016-10-28

Family

ID=43992414

Family Applications (1)

Application Number Title Priority Date Filing Date
PT108307778T PT2499165T (pt) 2009-11-13 2010-11-12 Preparações que contêm o fator de von willebrand (vwf), e métodos, kits e utilizações relacionadas com as mesmas

Country Status (20)

Country Link
US (1) US8759293B2 (pt)
EP (1) EP2499165B1 (pt)
JP (1) JP5876416B2 (pt)
KR (1) KR101808751B1 (pt)
CN (1) CN102648212B (pt)
AU (1) AU2010319425B2 (pt)
BR (1) BR112012011740A2 (pt)
CA (1) CA2780542C (pt)
CL (1) CL2012001258A1 (pt)
ES (1) ES2600879T3 (pt)
HK (1) HK1170244A1 (pt)
HU (1) HUE029454T2 (pt)
IL (1) IL219679A (pt)
MX (1) MX2012005527A (pt)
NZ (1) NZ600278A (pt)
PL (1) PL2499165T3 (pt)
PT (1) PT2499165T (pt)
RU (1) RU2579977C2 (pt)
WO (1) WO2011060242A2 (pt)
ZA (1) ZA201203795B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
SI2185589T1 (sl) 2007-06-01 2016-04-29 University Of Maryland Baltimore Vezavna sredstva za Fc receptor konstantne regije imunoglobulina
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
PL2499165T3 (pl) 2009-11-13 2017-04-28 Grifols Therapeutics Inc. Preparaty zawierające czynnik von willenbranda (vwf) oraz sposoby, zestawy i zastosowania z nim powiązane
CA2804512C (en) 2010-07-28 2015-11-24 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
WO2013098676A1 (en) 2011-12-30 2013-07-04 Grifols, S.A. Method for purifying factor viii
US11370827B2 (en) * 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
ES2899848T3 (es) 2012-01-12 2022-03-15 Bioverativ Therapeutics Inc Reducción de la inmunogenicidad contra el factor VIII en individuos sometidos a una terapia con factor VIII
EP3564260B1 (en) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
JP6603128B2 (ja) * 2012-07-11 2019-11-06 バイオベラティブ セラピューティクス インコーポレイテッド ＸＴＥＮおよびｖｏｎＷｉｌｌｅｂｒａｎｄ因子タンパク質を有する第ＶＩＩＩ因子の複合体、および、その使用
JP2015527366A (ja) 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子
CA2888982C (en) 2012-10-24 2020-07-21 Platelet Targeted Therapeutics, Llc Platelet targeted treatment
GB201304973D0 (en) * 2013-03-19 2013-05-01 Profactor Pharma Ltd Recombinant protein
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
JP2016522219A (ja) * 2013-06-12 2016-07-28 ノヴォ ノルディスク アー／エス 血友病の治療に適する化合物
IL297611A (en) * 2013-06-28 2022-12-01 Bioverativ Therapeutics Inc Binding of thrombin that degrades with castane and uses thereof
WO2014210547A1 (en) * 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
MY192481A (en) * 2014-01-10 2022-08-23 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
US10626164B2 (en) * 2014-07-25 2020-04-21 Csl Limited Purification of VWF
US9701933B2 (en) * 2014-09-19 2017-07-11 Sarfaraz K. Niazi Harvesting and purification or perfusion yielder (HAPPY) device
SG11201706659WA (en) * 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
DK3297656T3 (da) 2015-05-22 2020-03-09 CSL Behring Lengnau AG Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
BR112018013822A2 (pt) * 2016-01-07 2018-12-11 Csl Behring Recombinant Facility Ag ?polipeptídeo modificado, complexo, composição farmacêutica, métodos para tratamento de um distúrbio hemorrágico, para produção de um polipeptídeo e para aumento da meia-vida do fator viii, uso de um polipeptídeo modificado, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira?
US11034775B2 (en) 2016-06-07 2021-06-15 Gliknik Inc. Cysteine-optimized stradomers
WO2017222337A1 (ko) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
KR20190085021A (ko) 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
CN111132693A (zh) * 2017-04-20 2020-05-08 芝加哥大学 用与免疫治疗抗体连接的ecm亲和肽治疗癌症的方法和组合物
GB201707139D0 (en) * 2017-05-04 2017-06-21 Imp Innovations Ltd Polypeptides
ES2966835T3 (es) 2017-06-22 2024-04-24 CSL Behring Lengnau AG Modulación de la inmunogenicidad del FVIII por VWF truncado
WO2019010496A1 (en) * 2017-07-07 2019-01-10 Baxalta Incorporated TREATMENT OF PATIENTS WITH A SERIOUS FORM OF VON WILLEBRAND'S DISEASE UNRESENGING SURGICAL INTERVENTION BY RECOMBINANT VWF ADMINISTRATION
CA3081106A1 (en) * 2017-11-01 2019-05-09 Queen's University At Kingston Von willebrand factor proteins for treating bleeding disorders
US10654911B1 (en) * 2019-04-02 2020-05-19 Beijing Neoletix Biological Technology Co., Ltd. Vector co-expressing truncated von Willebrand factor and factor VIII
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2024106355A1 (ja) * 2022-11-14 2024-05-23 セルジェンテック株式会社 血液凝固第ｖｉｉｉ因子改変体を産生するエクスビボ遺伝子治療用細胞

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234991A (en) 1975-07-29 1993-08-10 Pasteur Merieux Serums And Vaccines Porous mineral support coated with an aminated polysaccharide polymer
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5149637A (en) 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
US5043429B1 (en) 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
FR2616437B1 (fr) 1987-06-11 1990-09-07 Ibf Polymeres composites, leur preparation et leur utilisation en chromatographie liquide
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5683912A (en) 1994-07-21 1997-11-04 The Salk Institute For Biological Studies Cloning and expression of a novel acetylcholine-gated ion channel receptor subunit
FR2632309B1 (fr) 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
ATE283864T1 (de) * 1991-06-20 2004-12-15 Aventis Behring L L C Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor
DE4204694C3 (de) * 1992-02-01 1995-10-12 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem Faktor VIII mittels Anionenaustauscher-Chromatographie
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5268097A (en) 1992-06-19 1993-12-07 Sepracor Inc. Passivated and stabilized porous mineral oxide supports and method for the preparation and use of same
WO1994011384A1 (en) 1992-11-13 1994-05-26 Immunex Corporation Novel cytokine designated elk ligand
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
US5849989A (en) 1994-10-07 1998-12-15 Ontogeny, Inc. Insulin promoter factor, and uses related thereto
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US6613508B1 (en) 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
CN1163619C (zh) 1996-01-23 2004-08-25 佳根基因组学公司 测定核酸分子序列的方法和组合物
US6312893B1 (en) 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
AT403765B (de) 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
AU3671197A (en) 1996-07-19 1998-02-10 Regents Of The University Of Michigan, The Dna encoding canine von willebrand factor and methods of use
US6074832A (en) 1996-07-19 2000-06-13 The Regents Of The University Of Michigan DNA encoding canine von Willebrand factor and methods of use
US6063593A (en) 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
ATE425990T1 (de) 1996-11-27 2009-04-15 Genentech Inc Affinitatsreinigung von polypeptid-proteinen auf einer matrix
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
US6489290B2 (en) 1997-03-27 2002-12-03 Trustees Of Boston University Antiplatelet agent
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
NZ501774A (en) 1997-07-22 2002-02-01 Qiagen Genomics Inc Computer method and system for correlating known characteristics of biomolecules to molecular tags with unique molecular weights that are associated with the biomolecule
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU775529B2 (en) 1998-11-10 2004-08-05 Stichting Sanquin Bloedvoorziening A factor VIII-polypeptide with factor VIII:C-activity
US7144996B1 (en) 1999-03-05 2006-12-05 Genentech, Inc. Nucleic acid encoding human suppressor of fused
US20050164386A1 (en) 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US20060099685A1 (en) 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2410440A1 (en) 2000-06-02 2001-12-13 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
US7498304B2 (en) 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
WO2002010437A2 (en) 2000-07-28 2002-02-07 Blood Center Research Foundation Synthetic and recombinant substrates for the detection of the von willebrand factor-cleaving protease
AUPR278301A0 (en) 2001-01-31 2001-02-22 Bionomics Limited A novel gene
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
WO2003025146A2 (en) 2001-09-18 2003-03-27 Avigenics, Inc. Production of a transgenic avian by cytoplasmic injection
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
WO2003047507A2 (en) 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
WO2003054232A2 (en) 2001-12-13 2003-07-03 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
DK1543106T3 (da) 2002-07-15 2007-08-13 Immunex Corp Fremgangsmåder og medier til kontrol af sialylering af proteiner, der dannes af mammaliaceller
EP3552627A1 (en) * 2003-05-06 2019-10-16 Bioverativ Therapeutics Inc. Clotting factor-fc chimeric proteins to treat hemophilia
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2005073528A (ja) * 2003-08-28 2005-03-24 Genetics Inst Llc 生物学的系における生物学的組織への血球の接着を阻害する方法、ならびにその方法に使用するための組成物
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP3184551A1 (en) 2004-08-12 2017-06-28 Lipoxen Technologies Limited Sialic acid derivatives
US20070066551A1 (en) 2004-09-07 2007-03-22 Keefe Anthony D Aptamer medicinal chemistry
GB0423974D0 (en) * 2004-10-28 2004-12-01 Ares Trading Sa Proteins
JP5022231B2 (ja) 2004-12-27 2012-09-12 バクスター・インターナショナル・インコーポレイテッド ポリマー−フォンビルブラント因子結合体
JP4829897B2 (ja) 2005-01-14 2011-12-07 アブリンクス ナームローゼ フェンノートシャップ 血小板減少及び／又はフォンビルブラント因子（ｖＷＦ）と血小板との間の自発的相互作用によって特徴づけられる疾患及び障害の異なる形態を区別する方法及びアッセイ
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US20080206246A1 (en) 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2007102946A2 (en) * 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
NZ574093A (en) 2006-06-12 2011-03-31 Symphogen As Pan-cell surface receptor- specific therapeutics
US8637007B2 (en) 2006-12-15 2014-01-28 Baxter International Inc. Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life
EP2097096B1 (en) * 2006-12-22 2017-05-31 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
DK2223108T3 (en) 2007-12-27 2016-07-18 Baxalta GmbH Methods for differentiation of plasma-derived protein from the recombinant protein in a sample
JP5784907B2 (ja) 2007-12-28 2015-09-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 組換え型ｖｗｆ製剤
ES2531464T3 (es) * 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
US20110086362A1 (en) 2009-10-09 2011-04-14 Massachusetts Institute Of Technology High-Throughput Method for Quantifying Sialylation of Glycoproteins
PL2499165T3 (pl) 2009-11-13 2017-04-28 Grifols Therapeutics Inc. Preparaty zawierające czynnik von willenbranda (vwf) oraz sposoby, zestawy i zastosowania z nim powiązane

Also Published As

Publication number Publication date
JP2013510581A (ja) 2013-03-28
EP2499165A4 (en) 2013-09-11
WO2011060242A3 (en) 2011-10-13
RU2012122402A (ru) 2013-12-20
CA2780542C (en) 2020-03-24
JP5876416B2 (ja) 2016-03-02
ZA201203795B (en) 2014-10-29
NZ600278A (en) 2014-04-30
CA2780542A1 (en) 2011-05-19
US8759293B2 (en) 2014-06-24
IL219679A (en) 2016-11-30
AU2010319425A1 (en) 2012-06-14
EP2499165A2 (en) 2012-09-19
MX2012005527A (es) 2012-08-08
CN102648212A (zh) 2012-08-22
KR20120113214A (ko) 2012-10-12
CL2012001258A1 (es) 2012-09-14
ES2600879T3 (es) 2017-02-13
EP2499165B1 (en) 2016-09-14
CN102648212B (zh) 2014-12-03
IL219679A0 (en) 2012-07-31
AU2010319425B2 (en) 2015-07-02
PL2499165T3 (pl) 2017-04-28
HK1170244A1 (zh) 2013-02-22
KR101808751B1 (ko) 2017-12-13
US20120289468A1 (en) 2012-11-15
BR112012011740A2 (pt) 2018-03-27
HUE029454T2 (en) 2017-03-28
WO2011060242A2 (en) 2011-05-19
RU2579977C2 (ru) 2016-04-10

Similar Documents

Publication Publication Date Title
ZA201203795B (en) Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
IL269858A (en) Pyridone and aza-pyridone compounds, pharmaceutical composition and kits comprising the same and uses thereof
HK1211228A1 (en) Factor viii complex with xten and von willebrand factor protein, and uses thereof xten viii
IL233934A0 (en) Antibodies to cd47, preparations containing them and their uses
GB2478230B (en) Gesture based edit mode
IL216014A0 (en) Antibodies immunorective with heregulin-her3 complexes, compositions comprising the same and uses thereof
AP2010005332A0 (en) Humanized antibodies specific for von willebrand factor.
IL226383B (en) Antibodies against ccl20, preparations containing them and their uses
EP2627358C0 (en) PRETARGETING KIT, METHOD AND MEANS USED THEREIN
IL225460A0 (en) Antibodies that bind to p4d12191, preparations containing them and their uses
TWI370040B (en) Simultanes doppelseitenschleifen von halbleiterscheiben
ZA201102081B (en) Engineered anti0il-13 antibodies,compositions,methods and uses
HK1183514A1 (en) Immunochromatography devices, methods and kits
SG10201709806VA (en) Hemagglutinin polypeptides, and reagents and methods relating thereto
PL2078730T3 (pl) Sposób otrzymywania koncentratu czynnika von Willebranda lub kompleksu czynnik VIII/ czynnik von Willebranda oraz ich zastosowanie
ZA201406381B (en) Levoisovalerylspiramycin i,ii,iii,and preparations,preparations methods and uses thereof
EP2601235A4 (en) EPOXYED COMPOSITION AND METHOD OF MANUFACTURING THEREOF
WO2012050963A3 (en) Agents providing controls and standards for immuno-precipitation assays
EP2193373A4 (en) METHODS AND KITS FOR MEASURING VON WILLEBRAND FACTOR
IL226498A0 (en) Bombycin analogues labeled with 177 lutetium, kits containing them and their uses
GB201119716D0 (en) Post and panel assembly and method, e.g. for glazed parapet
GB201007359D0 (en) Conjugated von willebrand factor